Q1 2026 Management View Brian Goff (CEO & Director) said the company is “off to a strong start entering another catalyst-rich year,” highlighting $20.7 million in net revenues and “138% growth ...
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, ...
U.S. Mitapivat Net Revenue -- $18.8 million, attributed to initial AQVESME demand. Operating Expenses -- R&D was $81 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results